Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) EBITDA Margin (2016 - 2026)

Integra Lifesciences Holdings' EBITDA Margin history spans 17 years, with the latest figure at 5.3% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 275.0% to 5.3% in Q4 2025 year-over-year; TTM through Dec 2025 was 30.34%, a 3031.0% decrease, with the full-year FY2025 number at 30.17%, down 3194.0% from a year prior.
  • EBITDA Margin hit 5.3% in Q4 2025 for Integra Lifesciences Holdings, up from 1.61% in the prior quarter.
  • Over the last five years, EBITDA Margin for IART hit a ceiling of 21.06% in Q1 2021 and a floor of 118.11% in Q2 2025.
  • Historically, EBITDA Margin has averaged 0.65% across 5 years, with a median of 6.44% in 2023.
  • Biggest five-year swings in EBITDA Margin: surged 2642bps in 2021 and later plummeted -11321bps in 2025.
  • Tracing IART's EBITDA Margin over 5 years: stood at 14.36% in 2021, then increased by 19bps to 17.04% in 2022, then tumbled by -47bps to 9.08% in 2023, then fell by -11bps to 8.05% in 2024, then tumbled by -34bps to 5.3% in 2025.
  • Business Quant data shows EBITDA Margin for IART at 5.3% in Q4 2025, 1.61% in Q3 2025, and 118.11% in Q2 2025.